Journal of acquired immune deficiency syndromes (1999)

publication venue for

Brief Report: Changes in Nocturnal Heart Rate Variability in People Living With HIV During the First Year of Antiretroviral Therapy Compared With HIV-Uninfected Community Controls.. 93. 2023
High specificity of HPV cell free DNA tests in persons with HIV for the detection of HPV-related cancer. 2023
Association of Pregnancy and HIV Status with Molecular-Bacterial Vaginosis in Indian Women. 2023
Prehypertension and Retinal Arteriolar Narrowing in PWH in Tanzania.. 91. 2022
Plasma Cell-Free Mitochondrial DNA as a Marker of Geriatric Syndromes in Older Adults With HIV.. 90. 2022
Effects of Sex, Existing Antibodies, and HIV-1-Related and Other Baseline Factors on Antibody Responses to Quadrivalent HPV Vaccine in Persons With HIV.. 89. 2022
Human Immunodeficiency Virus transmission by HIV Risk Group and Along the HIV Care Continuum: A Contrast of 6 US Cities.. 89. 2022
Urine Cell-Free Mitochondrial DNA as a Marker of Weight Loss and Body Composition in Older Adults With HIV.. 88. 2021
Outcomes After Second-Line Antiretroviral Therapy in Children Living With HIV in Latin America.. 87. 2021
Xpert HPV as a Screening Tool for Anal Histologic High-Grade Squamous Intraepithelial Lesions in Women Living With HIV.. 87. 2021
Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment.. 86. 2021
Brief Report: Relationship Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in Persons With HIV.. 84. 2020
Intestinal Dysbiosis and Markers of Systemic Inflammation in Viscerally and Generally Obese Persons Living With HIV.. 83. 2020
Brief Report: HIV Antibodies Decline During Antiretroviral Therapy but Remain Correlated With HIV DNA and HIV-Specific T-Cell Responses.. 81. 2019
ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial.. 81. 2019
Insomnia as an Independent Predictor of Incident Cardiovascular Disease in HIV: Data From the Veterans Aging Cohort Study.. 81. 2019
A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV.. 80. 2019
Characterizing Sociostructural Associations With New HIV Diagnoses Among Female Sex Workers in Cameroon.. 80. 2019
Medical Intensive Care Unit Admission Among Patients With and Without HIV, Hepatitis C Virus, and Alcohol-Related Diagnoses in the United States: A National, Retrospective Cohort Study, 1997-2014.. 80. 2019
A Successful Model of Expedited Antiretroviral Therapy for Clinically Stable Patients Living With HIV in Haiti.. 79. 2018
Improved Cognitive Performance and Reduced Monocyte Activation in Virally Suppressed Chronic HIV After Dual CCR2 and CCR5 Antagonism.. 79. 2018
Abdominal Fat Depots and Subclinical Carotid Artery Atherosclerosis in Women With and Without HIV Infection.. 77. 2018
Cryotherapy Reduces Progression of Cervical Intraepithelial Neoplasia Grade 1 in South African HIV-Infected Women: A Randomized, Controlled Trial.. 76. 2017
HIV and Obesity Comorbidity Increase Interleukin 6 but Not Soluble CD14 or D-Dimer.. 75. 2017
Prevalence of Anal HPV and Anal Dysplasia in HIV-Infected Women From Johannesburg, South Africa.. 75. 2017
A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults.. 74. 2017
Linkage to Primary Care and Survival After Hospital Discharge for HIV-Infected Adults in Tanzania: A Prospective Cohort Study.. 73. 2016
Brief Report: CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy.. 73. 2016
Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation.. 73. 2016
Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals.. 73. 2016
Brief Report: HIV-1 gp120 T-Cell Responses Correspond to Infection Outcomes in the Global iPrEx Chemoprophylaxis Trial.. 72. 2016
Do Biomarkers of Inflammation, Monocyte Activation, and Altered Coagulation Explain Excess Mortality Between HIV Infected and Uninfected People?. 72. 2016
Men's Understanding of and Experiences During the Postcircumcision Abstinence Period: Results From a Field Study of ShangRing Circumcision During Routine Clinical Services in Kenya and Zambia.. 72 Suppl 1. 2016
Surgical Outcomes of Newly Trained ShangRing Circumcision Providers.. 72 Suppl 1. 2016
Implementation and Operational Research: CD4 Count Monitoring Frequency and Risk of CD4 Count Dropping Below 200 Cells Per Cubic Millimeter Among Stable HIV-Infected Patients in New York City, 2007-2013.. 71. 2016
Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City.. 71. 2016
Clinical and Virologic Outcomes After Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America Network.. 71. 2016
Association of COPD With Risk for Pulmonary Infections Requiring Hospitalization in HIV-Infected Veterans.. 70. 2015
Impact of Illicit Drug Use on Health-Related Quality of Life in Opioid-Dependent Patients Undergoing HIV Treatment.. 70. 2015
Implementation and Operational Research: Postpartum Transfer of Care Among HIV-Infected Women Initiating Antiretroviral Therapy During Pregnancy.. 70. 2015
Use of a Comprehensive HIV Care Cascade for Evaluating HIV Program Performance: Findings From 4 Sub-Saharan African Countries.. 70. 2015
Implementation and Operational Research: Evaluation of Loss-to-Follow-up and Postoperative Adverse Events in a Voluntary Medical Male Circumcision Program in Nyanza Province, Kenya.. 69. 2015
Smartphone self-monitoring to support self-management among people living with HIV: perceived benefits and theory of change from a mixed-methods randomized pilot study.. 69 Suppl 1. 2015
HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction.. 68. 2015
Changes in metabolic syndrome status after initiation of antiretroviral therapy.. 68. 2015
Clinic-based routine voluntary HIV testing in a refugee settlement in Uganda.. 67. 2014
Field study of adult male circumcision using the ShangRing in routine clinical settings in Kenya and Zambia.. 67. 2014
Superior outcomes and lower outpatient costs with scale-up of antiretroviral therapy at the GHESKIO clinic in Port-au-Prince, Haiti.. 66. 2014
A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals.. 66. 2014
Cryptococcal meningitis management in Tanzania with strict schedule of serial lumber punctures using intravenous tubing sets: an operational research study.. 66. 2014
Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS.. 66. 2014
Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227.. 65. 2014
Randomized controlled trial of the shang ring versus conventional surgical techniques for adult male circumcision: safety and acceptability.. 65. 2014
Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.. 65. 2014
Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202.. 65. 2014
The role of HIV and monocytes/macrophages in adipose tissue biology.. 65. 2014
Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients.. 65. 2014
The Haiti research-based model of international public health collaboration: the GHESKIO Centers.. 65 Suppl 1. 2014
Effects of alcohol consumption on antigen-specific cellular and humoral immune responses to SIV in rhesus macaques.. 64. 2013
The acceptability and safety of the Shang Ring for adult male circumcision in Rakai, Uganda.. 63. 2013
Using a campaign approach among health workers to increase access to antiretroviral therapy for pregnant HIV-infected women in South Africa.. 63. 2013
Antiretroviral therapy for prevention of HIV and tuberculosis: a promising intervention but not a panacea.. 63 Suppl 2. 2013
Lives saved by expanding HIV treatment availability in resource-limited settings: the example of Haiti.. 63. 2013
IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients.. 63. 2013
Attrition from HIV testing to antiretroviral therapy initiation among patients newly diagnosed with HIV in Haiti.. 62. 2013
Retention of HIV-infected children on antiretroviral treatment in HIV care and treatment programs in Kenya, Mozambique, Rwanda, and Tanzania.. 62. 2013
Risk factors for hospitalization and medical intensive care unit (MICU) admission among HIV-infected Veterans.. 62. 2013
Consideration of postpartum management in HIV-positive Haitian women: an analysis of CD4 decline, mortality, and follow-up after delivery.. 61. 2012
Association of HIV infection with incident diabetes mellitus: impact of using hemoglobin A1C as a criterion for diabetes.. 61. 2012
Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals.. 61. 2012
Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City.. 61. 2012
Symptom screen for identification of highly infectious tuberculosis in people living with HIV in Southeast Asia.. 60. 2012
Comorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the Veterans Aging Cohort Study.. 60. 2012
Multiple determinants, common vulnerabilities, and creative responses: addressing the AIDS pandemic in diverse populations globally.. 60 Suppl 2. 2012
Using tuberculin skin test as an entry point to screen for latent and active tuberculosis in Thai people living with HIV.. 60. 2012
Randomized trial of the Shang Ring for adult male circumcision with removal at one to three weeks: delayed removal leads to detachment.. 60. 2012
Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study.. 59. 2012
Long-term antiretroviral treatment outcomes in seven countries in the Caribbean.. 59. 2012
No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.. 59. 2012
Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.. 58. 2011
Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.. 58. 2011
Leveraging progress in prevention of mother-to-child transmission of HIV for improved maternal, neonatal, and child health services.. 57 Suppl 2. 2011
Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States.. 57. 2011
The Shang Ring device for adult male circumcision: a proof of concept study in Kenya.. 57. 2011
The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation.. 56 Suppl 1. 2011
Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma.. 56. 2011
Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C).. 55. 2010
Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.. 55. 2010
Antiretroviral treatment 2010: progress and controversies.. 55 Suppl 1. 2010
Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.. 55. 2010
Implementation science for the prevention and treatment of HIV/AIDS.. 55 Suppl 1. 2010
Performance of abdominal ultrasound for diagnosis of tuberculosis in HIV-infected persons living in Cambodia.. 55. 2010
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.. 54. 2010
Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV.. 54. 2010
Undiagnosed HIV infection among New York City jail entrants, 2006: results of a blinded serosurvey.. 54. 2010
Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).. 53. 2010
Immune escape mutations detected within HIV-1 epitopes associated with viral control during treatment interruption.. 53. 2010
Risk factors for HIV infection among Haitian adolescents and young adults seeking counseling and testing in Port-au-Prince.. 52. 2009
Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy.. 52. 2009
Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean.. 51. 2009
Plasma homocysteine is not associated with HIV serostatus or antiretroviral therapy in women.. 51. 2009
Antiretroviral therapy for HIV-infected tuberculosis patients saves lives but needs to be used more frequently in Thailand.. 48. 2008
The HVTN protocol 903 vaccine preparedness study: lessons learned in preparation for HIV vaccine efficacy trials.. 48. 2008
Consistency of initial antiretroviral therapy with HIV treatment guidelines in a US cohort of HIV-infected women.. 47. 2008
Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in johannesburg, South Africa.. 47. 2008
Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095.. 46. 2007
Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.. 46. 2007
Analytic insights into the population level impact of imperfect prophylactic HIV vaccines.. 45. 2007
Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients.. 45. 2007
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).. 44. 2007
Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy.. 44. 2007
Predictors of antiretroviral treatment failure in an urban HIV clinic.. 44. 2007
Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients.. 43 Suppl 1. 2006
Contribution of bacterial sepsis to morbidity in infants born to HIV-infected Haitian mothers.. 43. 2006
Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa.. 43. 2006
The use of an educational video during informed consent in an HIV clinical trial in Haiti.. 42. 2006
Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study.. 41. 2006
Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359.. 40. 2005
Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries.. 40. 2005
Herpes zoster in women with and at risk for HIV: data from the Women's Interagency HIV Study.. 37. 2004
Case-control study of diabetes mellitus in HIV-infected patients.. 37. 2004
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.. 37. 2004
Infection with HIV type 1 group M non-B subtypes in individuals living in New York City.. 36. 2004
Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3.. 36. 2004
Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).. 36. 2004
Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIV.. 35. 2004
Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection.. 34. 2003
Colinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencing.. 34. 2003
The feasibility, demand, and effect of integrating primary care services with HIV voluntary counseling and testing: evaluation of a 15-year experience in Haiti, 1985-2000.. 33. 2003
Correlation of single photon emission computed tomography parameters as a noninvasive alternative to liver biopsies in assessing liver involvement in the setting of HIV and hepatitis C virus coinfection: a multicenter trial of the Adult AIDS Clinical Trials Group.. 33. 2003
Complementary and alternative medicine use and substitution for conventional therapy by HIV-infected patients.. 33. 2003
The diverse older HIV-positive population: a national profile of economic circumstances, social support, and quality of life.. 33 Suppl 2. 2003
Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients.. 32. 2003
Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection.. 30. 2002
The care of HIV-infected adults in rural areas of the United States.. 28. 2001
Underuse of primary Mycobacterium avium complex and Pneumocystis carinii prophylaxis in the United States.. 28. 2001
Screening for cervical cancer in HIV-infected women receiving care in the United States.. 27. 2001
Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401.. 27. 2001
Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization.. 25. 2000
Care of vaginal symptoms among HIV-infected women.. 25. 2000
Bacteremia in HIV-infected patients: short-term predictors of mortality.. 22. 1999
Dehydroepiandrosterone sulfate (DHEAS) and testosterone: relation to HIV illness stage and progression over one year.. 22. 1999
"FANMI": A Promising Differentiated Model of HIV Care for Adolescents in Haiti. 2019
Cost of an HIV Medical Care Coordination Program in Los Angeles County. 2019
PD-1+ and TIGIT+ CD4 T Cells Are Associated With Coronary Artery Calcium Progression in HIV-Infected Treated Adults. 2019
Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy. 2018
Availability of HIV and HCV On-Site Testing and Treatment at Syringe Service Programs in the United States. 2018
CD4/CD8 Ratio Predicts Peripheral Fat in HIV-Infected Population. 2016
Isolated Hepatitis B Core Antibody is Associated With Advanced Hepatic Fibrosis in HIV/HCV Infection But Not in HIV Infection Alone. 2016
Test, treat, and cure. 2015
Proper surgical training and grading of complications for Shang Ring circumcision are necessary. 2013
Maternal atazanavir usage in HIV-infected pregnant women and the risk of maternal and neonatal hyperbilirubinemia. 2013
Schistosomiasis and impaired response to antiretroviral therapy among HIV-infected patients in Tanzania. 2013
Minimally invasive male circumcision. 2012
Results from a New York City emergency department rapid HIV testing program. 2010
Response to "Micronutrient supplementation increases CD4 count in HIV-infected individuals on highly active antiretroviral therapy: a prospective, double-blinded, placebo-controlled trial". 2007
No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial. 2001
Peptides derived from salivary thrombospondin-1 replicate its anti-HIV effect: potential role in microbicide development. 2001
A computational future for preventing HIV in minority communities: how advanced technology can improve implementation of effective programs. 2013
What does U.S. health reform mean for HIV clinical care? 2012
Twenty-five years of HIV: lessons for low prevalence scenarios. 2009

VIVO Weill Cornell Medical College

Journal of acquired immune deficiency syndromes (1999) Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)